King BA - Search Results

1

A neutrophil activation signature predicts critical illness and mortality in COVID-19.

Meizlish ML, Pine AB, Bishai JD, Goshua G, Nadelmann ER, Simonov M, Chang CH, Zhang H, Shallow M, Bahel P, Owusu K, Yamamoto Y, Arora T, Atri DS, Patel A, Gbyli R, Kwan J, Won CH, Dela Cruz C, Price C, Koff J, King BA, Rinder HM, Wilson FP, Hwa J, Halene S, Damsky W, van Dijk D, Lee AI, Chun HJ. Meizlish ML, et al. Among authors: king ba. Blood Adv. 2021 Mar 9;5(5):1164-1177. doi: 10.1182/bloodadvances.2020003568. Blood Adv. 2021. PMID: 33635335 Free PMC article.

2

STATing the obvious: it's time for new treatments in atopic dermatitis.

Damsky W, King BA. Damsky W, et al. Among authors: king ba. Br J Dermatol. 2016 Nov;175(5):861-862. doi: 10.1111/bjd.15036. Br J Dermatol. 2016. PMID: 27790697 No abstract available.

3

Treatment of Hypereosinophilic Syndrome with Cutaneous Involvement with the JAK Inhibitors Tofacitinib and Ruxolitinib.

King B, Lee AI, Choi J. King B, et al. J Invest Dermatol. 2017 Apr;137(4):951-954. doi: 10.1016/j.jid.2016.10.044. Epub 2016 Nov 22. J Invest Dermatol. 2017. PMID: 27887955 Free PMC article. No abstract available.

4

Idiopathic erythema multiforme: Evidence of underlying Janus kinase-signal transducer and activator of transcription activation and successful treatment with tofacitinib.

Damsky W, King BA. Damsky W, et al. Among authors: king ba. JAAD Case Rep. 2016 Dec 7;2(6):502-504. doi: 10.1016/j.jdcr.2016.10.009. eCollection 2016 Nov. JAAD Case Rep. 2016. PMID: 28004029 Free PMC article. No abstract available.

5

JAK inhibitors in dermatology: The promise of a new drug class.

Damsky W, King BA. Damsky W, et al. Among authors: king ba. J Am Acad Dermatol. 2017 Apr;76(4):736-744. doi: 10.1016/j.jaad.2016.12.005. Epub 2017 Jan 28. J Am Acad Dermatol. 2017. PMID: 28139263 Free PMC article. Review.

6

Keratosis lichenoides chronica successfully treated with isotretinoin and methotrexate.

Li AW, Damsky W, King BA. Li AW, et al. Among authors: king ba. JAAD Case Rep. 2017 Apr 14;3(3):205-207. doi: 10.1016/j.jdcr.2017.02.009. eCollection 2017 May. JAAD Case Rep. 2017. PMID: 28443310 Free PMC article. No abstract available.

7

Treatment of generalized deep morphea and eosinophilic fasciitis with the Janus kinase inhibitor tofacitinib.

Kim SR, Charos A, Damsky W, Heald P, Girardi M, King BA. Kim SR, et al. Among authors: king ba. JAAD Case Rep. 2018 Apr 30;4(5):443-445. doi: 10.1016/j.jdcr.2017.12.003. eCollection 2018 Jun. JAAD Case Rep. 2018. PMID: 29984277 Free PMC article. No abstract available.

8

Tofacitinib Treatment and Molecular Analysis of Cutaneous Sarcoidosis.

Damsky W, Thakral D, Emeagwali N, Galan A, King B. Damsky W, et al. N Engl J Med. 2018 Dec 27;379(26):2540-2546. doi: 10.1056/NEJMoa1805958. N Engl J Med. 2018. PMID: 30586518 Free PMC article.

9

Targeted Treatment of TREX1 Chilblain Lupus and Other Interferonopathies-Taming T REX.

Damsky W, King BA. Damsky W, et al. Among authors: king ba. JAMA Dermatol. 2019 Mar 1;155(3):283-284. doi: 10.1001/jamadermatol.2018.4836. JAMA Dermatol. 2019. PMID: 30673073 No abstract available.

10

Janus kinase inhibition induces disease remission in cutaneous sarcoidosis and granuloma annulare.

Damsky W, Thakral D, McGeary MK, Leventhal J, Galan A, King B. Damsky W, et al. J Am Acad Dermatol. 2020 Mar;82(3):612-621. doi: 10.1016/j.jaad.2019.05.098. Epub 2019 Jun 8. J Am Acad Dermatol. 2020. PMID: 31185230 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

336 results

Search Page

Filters